DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry

Abstract

Background: Extracellular vesicles released by prostate cancer present in seminal fluid, urine, and blood may represent a non-invasive means to identify and prioritize patients with intermediate risk and high risk of prostate cancer. We hypothesize that enumeration of circulating prostate microparticles (PMPs), a type of extracellular vesicle (EV), can identify patients with Gleason Score≥4+4 prostate cancer (PCa) in a manner independent of PSA. Patients and Methods: Plasmas from healthy volunteers, benign prostatic hyperplasia patients, and PCa patients with various Gleason score patterns were analyzed for PMPs. We used nanoscale flow cytometry to enumerate PMPs which were defined as submicron events (100-1000nm) immunoreactive to anti-PSMA mAb when compared to isotype control labeled samples. Levels of PMPs (counts/µL of plasma) were also compared to CellSearch CTC Subclasses in various PCa metastatic disease subtypes (treatment naïve, castration resistant prostate cancer) and in serially collected plasma sets from patients undergoing radical prostatectomy. Results: PMP levels in plasma as enumerated by nanoscale flow cytometry are effective in distinguishing PCa patients with Gleason Score≥8 disease, a highrisk prognostic factor, from patients with Gleason Score≤7 PCa, which carries an intermediate risk of PCa recurrence. PMP levels were independent of PSA and significantly decreased after surgical resection ofmore » the prostate, demonstrating its prognostic potential for clinical follow-up. CTC subclasses did not decrease after prostatectomy and were not effective in distinguishing localized PCa patients from metastatic PCa patients. Conclusions: PMP enumeration was able to identify patients with Gleason Score ≥8 PCa but not patients with Gleason Score 4+3 PCa, but offers greater confidence than CTC counts in identifying patients with metastatic prostate cancer. CTC Subclass analysis was also not effective for post-prostatectomy follow up and for distinguishing metastatic PCa and localized PCa patients. Nanoscale flow cytometry of PMPs presents an emerging biomarker platform for various stages of prostate cancer.« less

Authors:
 [1];  [1];  [2];  [1];  [1];  [3];  [3];  [4];  [5];  [6];  [1];  [6];  [7];  [8];  [5];  [9];  [5];  [1]
  1. Western Univ., London (Canada). Dept. of Surgery; Lawson Health Research Inst., London (Canada). Translational Prostate Cancer Research Lab.
  2. Western Univ., London (Canada). Dept. of Surgery; Lawson Health Research Inst., London (Canada). Translational Prostate Cancer Research Lab.; Univ. of Damman (Saudi Arabia). Dept. of Urology
  3. Western Univ., London (Canada). Dept. of Mechanical and Materials Engineering
  4. Univ. Medical Center Freiburg (Germany). Dept. of Urology
  5. Western Univ., London (Canada). Dept. of Surgery; Western Univ., London (Canada). Dept. of Oncology; Lawson Health Research Inst., London (Canada). Translational Prostate Cancer Research Lab.
  6. Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
  7. Sandia National Laboratories, Albuquerque, NM, USA
  8. Univ. of Toronto, ON (Canada). Univ. Health Network
  9. Western Univ., London (Canada). Dept. of Oncology
Publication Date:
Research Org.:
Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
Sponsoring Org.:
USDOE Office of Science (SC)
OSTI Identifier:
1627990
Grant/Contract Number:  
NA0003525
Resource Type:
Accepted Manuscript
Journal Name:
Oncotarget
Additional Journal Information:
Journal Volume: 7; Journal Issue: 8; Journal ID: ISSN 1949-2553
Publisher:
Impact Journals
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; Oncology; Cell Biology

Citation Formats

Biggs, Colleen N., Siddiqui, Khurram M., Al-Zahrani, Ali A., Pardhan, Siddika, Brett, Sabine I., Guo, Qiu Q., Yang, Jun, Wolf, Philipp, Power, Nicholas E., Durfee, Paul N., MacMillan, Connor D., Townson, Jason L., Brinker, Jeffrey C., Fleshner, Neil E., Izawa, Jonathan I., Chambers, Ann F., Chin, Joseph L., and Leong, Hon S. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. United States: N. p., 2016. Web. doi:10.18632/oncotarget.6983.
Biggs, Colleen N., Siddiqui, Khurram M., Al-Zahrani, Ali A., Pardhan, Siddika, Brett, Sabine I., Guo, Qiu Q., Yang, Jun, Wolf, Philipp, Power, Nicholas E., Durfee, Paul N., MacMillan, Connor D., Townson, Jason L., Brinker, Jeffrey C., Fleshner, Neil E., Izawa, Jonathan I., Chambers, Ann F., Chin, Joseph L., & Leong, Hon S. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. United States. https://doi.org/10.18632/oncotarget.6983
Biggs, Colleen N., Siddiqui, Khurram M., Al-Zahrani, Ali A., Pardhan, Siddika, Brett, Sabine I., Guo, Qiu Q., Yang, Jun, Wolf, Philipp, Power, Nicholas E., Durfee, Paul N., MacMillan, Connor D., Townson, Jason L., Brinker, Jeffrey C., Fleshner, Neil E., Izawa, Jonathan I., Chambers, Ann F., Chin, Joseph L., and Leong, Hon S. Fri . "Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry". United States. https://doi.org/10.18632/oncotarget.6983. https://www.osti.gov/servlets/purl/1627990.
@article{osti_1627990,
title = {Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry},
author = {Biggs, Colleen N. and Siddiqui, Khurram M. and Al-Zahrani, Ali A. and Pardhan, Siddika and Brett, Sabine I. and Guo, Qiu Q. and Yang, Jun and Wolf, Philipp and Power, Nicholas E. and Durfee, Paul N. and MacMillan, Connor D. and Townson, Jason L. and Brinker, Jeffrey C. and Fleshner, Neil E. and Izawa, Jonathan I. and Chambers, Ann F. and Chin, Joseph L. and Leong, Hon S.},
abstractNote = {Background: Extracellular vesicles released by prostate cancer present in seminal fluid, urine, and blood may represent a non-invasive means to identify and prioritize patients with intermediate risk and high risk of prostate cancer. We hypothesize that enumeration of circulating prostate microparticles (PMPs), a type of extracellular vesicle (EV), can identify patients with Gleason Score≥4+4 prostate cancer (PCa) in a manner independent of PSA. Patients and Methods: Plasmas from healthy volunteers, benign prostatic hyperplasia patients, and PCa patients with various Gleason score patterns were analyzed for PMPs. We used nanoscale flow cytometry to enumerate PMPs which were defined as submicron events (100-1000nm) immunoreactive to anti-PSMA mAb when compared to isotype control labeled samples. Levels of PMPs (counts/µL of plasma) were also compared to CellSearch CTC Subclasses in various PCa metastatic disease subtypes (treatment naïve, castration resistant prostate cancer) and in serially collected plasma sets from patients undergoing radical prostatectomy. Results: PMP levels in plasma as enumerated by nanoscale flow cytometry are effective in distinguishing PCa patients with Gleason Score≥8 disease, a highrisk prognostic factor, from patients with Gleason Score≤7 PCa, which carries an intermediate risk of PCa recurrence. PMP levels were independent of PSA and significantly decreased after surgical resection of the prostate, demonstrating its prognostic potential for clinical follow-up. CTC subclasses did not decrease after prostatectomy and were not effective in distinguishing localized PCa patients from metastatic PCa patients. Conclusions: PMP enumeration was able to identify patients with Gleason Score ≥8 PCa but not patients with Gleason Score 4+3 PCa, but offers greater confidence than CTC counts in identifying patients with metastatic prostate cancer. CTC Subclass analysis was also not effective for post-prostatectomy follow up and for distinguishing metastatic PCa and localized PCa patients. Nanoscale flow cytometry of PMPs presents an emerging biomarker platform for various stages of prostate cancer.},
doi = {10.18632/oncotarget.6983},
journal = {Oncotarget},
number = 8,
volume = 7,
place = {United States},
year = {Fri Jan 22 00:00:00 EST 2016},
month = {Fri Jan 22 00:00:00 EST 2016}
}

Works referenced in this record:

Refractive index of tissue measured with confocal microscopy
journal, January 2005

  • Dirckx, Joris J. J.; Kuypers, Liesbeth C.; Decraemer, Willem F.
  • Journal of Biomedical Optics, Vol. 10, Issue 4
  • DOI: 10.1117/1.1993487

Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease
journal, May 2015


Validation of flow cytometric detection of platelet microparticles and liposomes by atomic force microscopy
journal, December 2011


All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer
journal, September 2010

  • Coumans, F. A. W.; Doggen, C. J. M.; Attard, G.
  • Annals of Oncology, Vol. 21, Issue 9
  • DOI: 10.1093/annonc/mdq030

Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing
journal, July 2014

  • van der Pol, E.; Coumans, F. A. W.; Grootemaat, A. E.
  • Journal of Thrombosis and Haemostasis, Vol. 12, Issue 7
  • DOI: 10.1111/jth.12602

Exosomes as Biomarker Treasure Chests for Prostate Cancer
journal, May 2011


The proteomics of prostate cancer exosomes
journal, February 2014


Re: Complications after Prostate Biopsy: Data from SEER-Medicare
journal, August 2012


Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen
journal, April 2001


Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy
journal, February 2012

  • Lowes, Lori E.; Lock, Michael; Rodrigues, George
  • Clinical and Translational Oncology, Vol. 14, Issue 2
  • DOI: 10.1007/s12094-012-0775-5

Prostasomes are heterogeneous regarding size and appearance but affiliated to one DNA-containing exosome family
journal, April 2012

  • Ronquist, Göran K.; Larsson, Anders; Stavreus-Evers, Anneli
  • The Prostate, Vol. 72, Issue 16
  • DOI: 10.1002/pros.22526

Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease
journal, November 2012

  • Di Vizio, Dolores; Morello, Matteo; Dudley, Andrew C.
  • The American Journal of Pathology, Vol. 181, Issue 5
  • DOI: 10.1016/j.ajpath.2012.07.030

Complications After Prostate Biopsy: Data From SEER-Medicare
journal, November 2011


Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
journal, April 1991

  • Catalona, William J.; Smith, Deborah S.; Ratliff, Timothy L.
  • New England Journal of Medicine, Vol. 324, Issue 17
  • DOI: 10.1056/NEJM199104253241702

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer
journal, September 2010

  • Coumans, F. A. W.; Doggen, C. J. M.; Attard, G.
  • Annals of Oncology, Vol. 21, Issue 9
  • DOI: 10.1093/annonc/mdq030

Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy
journal, February 2012

  • Lowes, Lori E.; Lock, Michael; Rodrigues, George
  • Clinical and Translational Oncology, Vol. 14, Issue 2
  • DOI: 10.1007/s12094-012-0775-5

Exosomes as Biomarker Treasure Chests for Prostate Cancer
journal, May 2011


Prostasomes are heterogeneous regarding size and appearance but affiliated to one DNA-containing exosome family
journal, April 2012

  • Ronquist, Göran K.; Larsson, Anders; Stavreus-Evers, Anneli
  • The Prostate, Vol. 72, Issue 16
  • DOI: 10.1002/pros.22526

Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing
journal, July 2014

  • van der Pol, E.; Coumans, F. A. W.; Grootemaat, A. E.
  • Journal of Thrombosis and Haemostasis, Vol. 12, Issue 7
  • DOI: 10.1111/jth.12602

A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer
journal, June 2011


The proteomics of prostate cancer exosomes
journal, February 2014


Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer
journal, November 2009

  • Wolf, Philipp; Freudenberg, Nikolaus; Bühler, Patrick
  • The Prostate, Vol. 70, Issue 5
  • DOI: 10.1002/pros.21090

Validation of flow cytometric detection of platelet microparticles and liposomes by atomic force microscopy
journal, December 2011


Refractive index of tissue measured with confocal microscopy
journal, January 2005

  • Dirckx, Joris J. J.; Kuypers, Liesbeth C.; Decraemer, Willem F.
  • Journal of Biomedical Optics, Vol. 10, Issue 4
  • DOI: 10.1117/1.1993487

Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease
journal, November 2012

  • Di Vizio, Dolores; Morello, Matteo; Dudley, Andrew C.
  • The American Journal of Pathology, Vol. 181, Issue 5
  • DOI: 10.1016/j.ajpath.2012.07.030

Works referencing / citing this record:

Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
journal, April 2017

  • Minciacchi, V. R.; Zijlstra, A.; Rubin, M. A.
  • Prostate Cancer and Prostatic Diseases, Vol. 20, Issue 3
  • DOI: 10.1038/pcan.2017.7

Extracellular vesicles in urological malignancies: an update
journal, December 2019


Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases
journal, February 2019


A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens
journal, March 2019

  • Jimenez, Rafael E.; Atwell, Thomas D.; Sicotte, Hughes
  • Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol. 3, Issue 1
  • DOI: 10.1016/j.mayocpiqo.2018.12.005

Extracellular Vesicle Quantification and Characterization: Common Methods and Emerging Approaches
journal, January 2019


Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management
journal, June 2018


Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases
journal, June 2017

  • Choi, Ji-Young; Kim, Sujin; Kwak, Hyo-Bum
  • International Neurourology Journal, Vol. 21, Issue 2
  • DOI: 10.5213/inj.1734961.458

The role of extracellular vesicles in cancer microenvironment and metastasis: myths and challenges
journal, January 2019

  • Lucien, Fabrice; Leong, Hon S.
  • Biochemical Society Transactions, Vol. 47, Issue 1
  • DOI: 10.1042/bst20180253

Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
text, January 2017


Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
journal, April 2017

  • Minciacchi, V. R.; Zijlstra, A.; Rubin, M. A.
  • Prostate Cancer and Prostatic Diseases, Vol. 20, Issue 3
  • DOI: 10.1038/pcan.2017.7

Extracellular Vesicle Quantification and Characterization: Common Methods and Emerging Approaches
journal, January 2019


Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients
journal, September 2019

  • Joncas, France‐Hélène; Lucien, Fabrice; Rouleau, Mélanie
  • The Prostate, Vol. 79, Issue 15
  • DOI: 10.1002/pros.23901

Plasticity in the Glucagon Interactome Reveals Novel Proteins That Regulate Glucagon Secretion in α-TC1-6 Cells
journal, January 2019


Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management
journal, June 2018


Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma
journal, January 2019

  • Padda, Ranjit S.; Deng, Florence K.; Brett, Sabine I.
  • The Prostate, Vol. 79, Issue 6
  • DOI: 10.1002/pros.23764